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1. Introduction
Tissue parasites such as Leishmania are transmitted from host to host through a vector species,
and transmission can be from human to vector to animal or vice versa (zoonotic transmission),
which occurs in rural and periurban environments or from human to vector to human
(anthroponotic transmission), which occurs in urban environments. Lutzomyia and Phleboto‐
mus species have long been known as the primary transmitters of leishmaniasis. However, in
recent decades, evidence has been building for the existence of alternative transmission
pathways. These pathways involve direct contact with infected tissues, such as may be
encountered during surgical/therapeutic procedures, biological/reproductive activities,
certain work-related practices and by unsafe drug use, all of which are reviewed below.
2. Transmission forms
2.1. The life cycle of Leishmania spp.: the vector transmission
Leishmania spp. is a parasite with a dimorphic life cycle that is controlled by the passage from
vector to host [1]. As such, the parasite has developed novel adaptations to survive within the
vector [2]. The vector phase of the life cycle begins when the vector ingests blood containing
the parasites. Following ingestion, the parasites eventually reach the midgut, where they are
held for approximately 4 hours in the peritrophic matrix. There, the amastigote cells differen‐
tiate into small, motile cells with short flagella, a form known as the procyclic promastigote.
Next, Leishmania initiates the first stage of the vector life cycle, which occurs over the following
24-48 hours. The body of the parasite elongates in the next 72 hours to form the nectomonad
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promastigote, and the microorganism then breaks down the peritrophic matrix to reach the
midgut lumen and migrate into the thoracic region of the vector. Once there, the promastigotes
differentiate into leptomonad promastigotes by decreasing in size and changing the location
of their flagella, which is followed by a second replication cycle during days 5-7. This process
produces a massive infection in the anterior portion of the midgut, where the parasites
differentiate into metacyclic promastigotes within the stomodeal valve, ensuring a large
number of parasites for the purpose of infection. To protect the metacyclic promastigotes, the
leptomonads also differentiate into gel-producing promastigotes, which surround the
leptomonad and metacyclic promastigotes. The latter cell type is considered to be the infective
form of the parasite because it possesses an elongated flagellum, which allows for motility and
resistance to complement-mediated lysis. When metacyclic promastigotes differentiate into
haptomonad promastigotes, they form parasitic rings that plug the stomodeal valve, eventu‐
ally leading to its degeneration. Finally, this process allows the parasites to pass into the
proboscis [2], where they can inoculate the host during feeding of the vector.
Upon entering the host, the parasite first encounters a host immune reaction following
activation of the complement system. With respect to this process, four distinct activation
pathways have been identified: the classical pathway, the alternative pathway, the lectin
pathway and the extrinsic pathway [3]. In humans, the parasite can evade the immune
response by inhibiting complement-mediated lysis, which occurs within the phagolysosomes
of macrophages. This protective effect is conferred by the membrane protease gp63, or
leishmanolysin, which inhibits attacks against the parasite cell membrane by adhering to
complement components [4]. Promastigote-stage parasites differentiate into small, round cells
3-5 µm in size that lack flagella, known as amastigotes. This form can be readily observed
within host cells by microscopy, where they are referred to as Leishman-Donovan [5] bodies.
Finally, when multiplication of the parasites exceeds the holding capacity of the phagocytic
cell, cell lysis occurs, releasing the parasites to infect new cells.
By some conservative estimates, a vector might release between 1-1000 metacyclic promasti‐
gotes into the host during feeding [6-7]. However, other estimates based on molecular biology
techniques indicate that a vector might release as many as 600 to 100,000 metacyclic promas‐
tigotes during a feeding period and that this number varies as function of feeding time. In
addition, it is known that large numbers of parasites actually increase vector feeding time, as
the parasites physically obstruct proper functioning of the proboscis [8]. Therefore, based on
these findings, between 100 and 100,000 metacyclic parasites are commonly used to inoculate
the footpads or pinnae of animals in in vivo models of infection [8-10].
2.2. Organ transplants, blood transfusions and hemodialysis
Therapeutic advances in a wide variety of medical fields have dramatically improved overall
quality of life and life expectancy in modern societies. This has partly been achieved through
the development of techniques such as organ transplantation, hemodialysis, and blood
transfusion, which are particularly useful for the treatment of chronic disease. However, the
transmission of infectious diseases during such procedures must account for and avoided.
Furthermore, human migration can easily transport diseases transmitted by vectors from
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endemic locations to non-endemic locations, as often happens with protozoan parasites of the
blood, such as Leishmania [11-12], Trypanosoma and Plasmodium [3].
During organ transplantations, there are several possible ways in which microorganisms such
as Leishmania can be transmitted, including reactivation of dormant parasites in the recipient
following treatment with immunosuppressants, infection by parasites derived from the donor,
transmission of parasites through blood transfusions during the surgical procedure and de
novo transmission [11-12]. Leishmania infections have been observed in individuals who have
undergone kidney [13-16] and liver [17-18] transplants, as well as in patients that have
undergone heart [17, 19-23], lung [24], pancreas [25], stem cell [26-27] and bone-marrow
transplants, although these are less common. Overall, the number of leishmaniasis cases
resulting from organ transplants is estimated to be fewer than 100 in total [11, 13-16], which
were mainly associated with kidney transplants. A primary risk factor for transmission is
whether the donor had lived in an area where leishmaniasis was endemic. However, this
subject is not commonly addressed during screening processes, and relevant laboratory tests
are not usually carried out on organ donors [28]. Therefore, it is important to generate and
review epidemiological data concerning leishmaniasis, as the number of infected individuals
who are asymptomatic could be even greater than the number of those showing clinical
symptoms [17]. There have also been reports of organ donors who were asymptomatic before
surgery but who died of leishmaniasis several months after the transplantation procedure.
Furthermore, there has been at least one case in which an organ recipient developed leishma‐
niasis symptoms two years after the transplantation procedure [29]. In cases where individuals
show symptoms approximately one month after transplantation, transmission is generally
considered to be due to the reactivation of dormant parasites within the recipient [30]. On the
other hand, in cases where leishmaniasis symptoms are observed approximately 18 months
after receiving a new organ, transmission is generally considered to be due to the de novo
acquisition of parasites [11-12, 16]. In either case, the suggested course of treatments to favour
transplant survival includes corticosteroids [24], immunosuppressants [13-14], or monoclonal
antibodies [11], which favor the development of leishmaniasis.
Infrequent or atypical symptoms can cause delayed diagnosis of leishmaniasis. The primary
clinical signs and symptoms related to Leishmania infections due to organ transplantation are
fever, splenomegaly, hepatomegaly, leukopenia and hypoalbuminemia [14, 31-32]. Unfortu‐
nately, the therapeutic responses to such cases are often insufficient to save the patient’s life,
which can be ascribed to late diagnoses, particularly severe infections and other health
complications [13] due to prolonged immunosuppressive regimens [16, 24].
Blood volume loss or deficiencies in specific blood components are indicators that a transfusion
of blood or blood-derivatives from a donor to a recipient may be necessary. Blood transfusions
are frequently performed during or after surgical interventions, and in the case of leishmaniasis
patients with a history of organ transplantation and blood transfusion, the disease is generally
considered to be a complication of the transplantation process [15, 32-33]. In patients without
such a background, infections are generally considered to have occurred through the transfu‐
sion of blood or blood-derived products. The first case of Leishmania transmission via a blood
transfer was documented in China in 1948, when two girls were given 20 mL of blood
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intramuscularly to stimulate passive immunity against measles and rubella. The blood came
from their mother, who was hospitalized days later with symptoms suggestive of visceral
leishmaniasis; this diagnosis was made one month after her being hospitalized. Therefore, due
to the medical history of the mother, the girls were monitored over the subsequent months.
Both girls developed leishmaniasis 9-10 months after the blood transfer [34]. Although this
case was not due to blood transfusion per se, it is the first documented case in which the use of
blood components for therapeutic purposes resulted in the contraction of leishmaniasis.
In general, the causative agents of visceral leishmaniasis belong to the donovani complex of
species, although there have also been reports of visceralization in species more typically
related to the mucocutaneous and cutaneous clinical presentations of the disease. These types
of clinical presentations have primarily been observed in individuals with compromised
immune systems, such as HIV-positive patients. However, there has been a single reported
case of a patient with these characteristics who also had a history of kidney transplantation
and blood transfusions. Furthermore, there was no history of vector exposure as the patient
was not living in an endemic region. The infection hypothesis was ruled out by searching for
signs of Leishmania in the blood by PCR and by searching for Leishmania-specific antibodies in
the donor and in the recipient of the second kidney. The patient’s death was caused by
complications due to the presence of T. cruzi, S. aureus and L. mexicana. Although the patient’s
transfusion donors could not be evaluated, based on analysis of other possible transmission
pathways, it was concluded that the most likely pathway of infection was through blood
transfusion [35].
Among other notable cases of secondary leishmaniasis due to blood products and transfusions,
there was the case of a patient with an autoimmune disease, idiopathic thrombocytopenic
purpura. The patient was transfused with concentrated platelets on multiple occasions over
the 2-3 year period prior to the development of leishmaniasis, a diagnosis that was confirmed
by bone marrow aspiration [36].
Another case involved an infant who received a blood transfusion within 7 days of birth due
to integument pallor with a subsequent diagnosis of myelofibrosis. The blood donor was a
relative who died three months after the donation, after developing hepatosplenomegaly,
pyrexia and a fever of unknown origin; the diagnosis was made postmortem after the detection
of Leishman-Donovan bodies. The infant began to show abdominal distension, fever and
integument pallor one month after the transfusion. At 5 months of age, visceral leishmaniasis
was diagnosed from a spleen aspirate that scored positive for Leishman-Donovan bodies.
Leishmaniasis treatment was initiated without improvement, and two months later, the infant
was rehospitalized with anemia, respiratory distress, hepatomegaly and splenomegaly. A liver
biopsy revealed changes consistent with steatohepatitis with necrotic foci and lipid granulo‐
mas. Furthermore, the biopsy was positive for anti-Leishmania antibodies (rK-39), whereas the
infant’s family members were negative for these antibodies. Due to a severe anemic syndrome,
the infant was given a blood transfusion. Despite treatment with antimonials, the infant
showed no improvement and indeed worsened with the development of septicemia caused
by Staphylococcus, Klebsiella and Pseudomonas. A change of drugs to Amphotericin B only
deteriorated the infant’s health further, and it died one month after admission [37].
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In a case involving an elderly patient, a 77-year-old woman with a history of chronic atrial
fibrillation, hypertension and chronic kidney disease with hemodialysis treatment underwent
surgery due to cholecystitis, during which time she received two units of blood. A month and
a half later, she presented with fever, diaphoresis and chills during a hemodialysis session and
over the next 24 hours; she also showed occasional diarrhea and weight loss. These symptoms
did not improve despite treatment with antibiotics. In the intensive care unit following
hemodialysis, the patient showed thrombocytopenia and hypotension with good ventricular
systolic function, requiring volume recovery and vasopressor therapy; hydrocortisone was
also included in the treatment. A bone marrow aspirate confirmed the presence of intracellular
amastigotes and numerous extracellular promastigotes, although these were not observed in
the peripheral blood. Treatment with Amphotericin B increased her platelet numbers,
although hemodynamic deterioration continued until the patient’s death. Cultures begun
previous to death showed the presence of Acinetobacter baumannii, a bacterium that is resistant
to multiple types of antibiotics. During a postmortem examination, the presence of Leishmania
parasites in the bile was tested for due to prior gastrointestinal symptoms. The transmission
of Leishmania through the blood was confirmed when one of her donors (to the source of the
units transfused during the cholecystectomy) tested positive for Leishmania-specific antibodies
[38].
Seven U.S. military groups assigned to Operation Desert Storm in the 1990s developed atypical
clinical presentations of L. donovani infection that were suggestive of Kala-azar. The symptoms
included stiffness, nonproductive cough, diffuse abdominal tenderness, diarrhea, nausea,
headache, myalgia, and arthralgia without organomegaly. One of the patients was asympto‐
matic, whereas two had diseases that compromised their immune systems: renal carcinoma
and HIV. The diagnoses were performed using an immunofluorescent antibody test (IFAT).
In all cases, the onset of symptoms occurred 1-14 months after their time in Saudi Arabia, and
none showed lesions that may have aided in the diagnosis of leishmaniasis [39]. These clinical
cases led U.S. authorities to recommend that all candidates who had visited the Persian Gulf
be rejected as blood donors. This situation was further complicated by the fact that the
conditions under which the Leishmania parasite might survive in blood products in bank bloods
were unknown. As a result, in vitro assays were performed on parasites isolated from the
soldiers. The Leishmania parasites that were isolated from the individuals participating in
Operation Desert Storm included L. tropica, L. major and L. donovani. These parasites were
maintained in log-phase culture and used to inoculate donated blood samples, which were
then stored at 4ºC for 35 days or at 24ºC for 5 days. It was observed that in whole-blood units
stored under these common blood-bank conditions, L. tropica intracellular parasites within
monocytes could survive up to 30 days at 4ºC and up to 5 days at 24ºC, in contrast to promas‐
tigotes in stationary phase or free amastigotes that does not. With respect to fresh frozen
plasma, it was observed that intracellular parasites could survive inside monocytes for 25 days
at 4ºC and for at least 5 days in the platelet fraction at 24ºC. For erythrocyte fractions frozen
with glycerol, survival time of the parasite was 35 days at 4ºC [40]. It is clear that Leishmania
shows low-temperature resistance, highlighting the very real possibility of parasite transmis‐
sion from infected individuals, either in the preclinical or asymptomatic phase, to immuno‐
compromised individuals via blood products.
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Transmission of Leishmania via blood transfusions has been demonstrated in domestic animals
[41] and model organisms, and these typically present symptoms following treatment with
either infected human blood or blood from experimentally infected animals [40, 42-43]. For
example, blood transfusions can be carried out in rodents by transferring 0.1-1.0 mL blood via
tail-vein [40] or intracardiac injection [43]. In a study involving hamsters, all groups that
received infected blood showed symptoms between 90-120 days following transfusion [43]. It
was found that 22.1% of the transfused hamsters scored positive for Leishmania by PCR
analysis, and 14.75% remained positive when the test was performed again after 12 months.
All of the monocyte cultures were negative. Furthermore, it was demonstrated that 29.5% of
the transfused hamsters tested positive by at least one of the techniques, with PCR being the
most sensitive assay [44].
There have also been various clinical studies carried out on individuals attending blood banks
in which the presence of the parasite was assessed for using techniques such as ELISA (enzyme-
linked immunosorbent assay) [45], IFAT [46], Western blotting, culturing and PCR [44-45].
ELISA experiments showed that 2.4% of the individuals had Leishmania-specific antibodies,
whereas 3.5% scored positive by Western blotting analysis; both tests showed a seroprevalence
of 7.6%.
Furthermore, questioning may be insufficient to exclude donors that have visited endemic
areas within the last 12 months or that have had clinical diagnoses of leishmaniasis, as
recommended by the WHO publication Blood donor selection: guidelines on assessing donor
suitability for blood donation. Therefore, there is a clear need to develop laboratory techniques
to identify this microorganism in blood or derivatives, and indeed, several studies have been
carried out to detect the presence of Leishmania-specific antibodies in healthy individuals who
have donated blood.
In cutaneous species, such as those belonging to the L. mexicana complex, it is unknown
whether the parasite can be transmitted through blood in humans under the same conditions
as the visceral species. However, as was previously mentioned, it should be noted that there
are cases of HIV patients that have developed visceral leishmaniasis when infected with
cutaneous species [35].
In individuals with chronic kidney disease, hemodialysis is a therapy that can greatly improve
patient prognosis and prolong and improve their quality of life. However, like many other
therapeutic procedures, hemodialysis can have adverse effects, including bacteremia and
sepsis due to poor aseptic techniques during treatment [47]. Indeed, it has been documented
that if proper care is not taken to sterilize hemodialysis equipment, including the cleaning and
replacement of disposable parts, there is high risk of acquiring infectious/contagious diseases
[47], including parasitic infections. Unlike with the situation with Toxoplasma, [48] Leishmania
has not been directly linked to hemodialysis patients, although large assays for Leishmania-
specific antibodies have been performed [49-50] that found the parasite in 9-25% of patients in
endemic areas [50]. Despite the fact that no studies directly link Leishmania infection to
hemodialysis treatment, perhaps because most patients with kidney disease who are treated
with hemodialysis also have a clinical history of immunosuppressive blood treatment, organ
transplantation and multiple blood transfusions [38, 50-51]. All of these conditions increase
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the possibility of acquiring leishmaniasis and negatively affect patient health, making the
analysis of causal factors difficult.
2.3. Sexual transmission
2.3.1. Leishmaniasis in sexual organs in humans
Cases of leishmaniasis of the sexual organs have been reported, manifesting as lesions on the
genitals, and such cases have been reported in both humans [52-56] and in animals [57-58].
Three possible mechanisms for the development of leishmaniasis of the sexual organs and
genitals have been suggested: (1) local infection derived from a wider systemic infection; (2)
infection due to exposure of the genitals to a vector in an endemic area; and (3) infection due
to direct contact of the genitals with an ulcerated lesion during intercourse [59].
By questioning patients, such cases of genital leishmaniasis in humans could not always be
directly linked to either intercourse [52-53] or to sleeping naked in endemic areas [55].
However, in cases where the lesions were observed on the vulvar regions [53], direct vector-
mediated infection can be ruled out, leaving open the possibility for localized infection of
systemic origin or from intercourse with a previously infected individual.
It should be noted that genital ulcers can have numerous causes, and thorough diagnoses
should be conducted in all cases to avoid confusion with other diseases, such as squamous cell
carcinoma or primary syphilis [55]. Likewise, the presence of other types of infectious
microorganisms should also be ruled out [59].
2.3.2. Leishmaniasis in sexual organs in animals
Among animals, domestic dogs are considered to be the main reservoir of Leishmania, and this
parasite has been detected in canine sexual organs as well [57-58]. In females, the absence of
exposed genitals and internal sex organs suggests that infections are either systemic in origin
or sexually transmitted, which is especially true in non-endemic areas [60-61].
It has been observed that when L. chagasi infects sexual organs (e.g., the testis, epididymis and
prostate) and genitals (e.g., the glans and foreskin), it can induce an inflammatory response.
In addition, macrophages infested with parasites accompanied by neutrophils in the foreskin
have also been observed in dogs. In one study involving dog semen, the presence of the parasite
was detected by PCR in 8 out of 22 samples analyzed [57], a finding which suggests the
possibility of sexual infection between animals. Indeed, when 12 serologically negative females
were mated to males that tested serologically positive for L. chagasi, 165 days after mating, 3
out of the 12 females were serologically positive and 6 out of the 12 females scored positive by
PCR [62]. Although the external genitals and the vulva are the most commonly affected areas
in symptomatic and asymptomatic females, females that scored positive for Leishmania by PCR
also showed effects in at least one other region of the reproductive system. Histological changes
included perifollicular lymphocytic infiltration with intracellular parasites as well as inflam‐
matory infiltration in the vulvar dermis [58]. Other trials have been carried out in which male
and female dogs infected with Leishmania were mated to observe vertical transmission.
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However, it remains unclear whether sexual transmission plays an important role in vertical
transmission [63].
2.4. Congenital transmission
2.4.1. Congenital leishmaniasis in humans
Vertical transmission is defined as the congenital transmission of a pathogenic microorganism,
condition, or characteristic from one generation to the next via the placenta, hematogenous,
the birth canal, or nursing at the maternal breast [64]. Vertical transmission has been demon‐
strated for visceral leishmaniasis caused by L. donovani and L. infantum. The first case of vertical
transmission in leishmaniasis was reported in 1926 in a pregnant woman who began to show
symptoms suggestive of leishmaniasis during her first trimester. The treatment for visceral
leishmaniasis was administered upon the exclusion of malaria and typhoid fever as differential
diagnoses by laboratory results. Upon treatment, the symptoms disappeared, and the preg‐
nancy continued to term. The birth took place without complications via the vaginal canal, and
the neonate was of normal weight. However, both mother and neonate exhibited a general
state of deterioration immediately postpartum. Visceral leishmaniasis was not suspected, and
the symptoms were fever, diarrhea, and abdominal pain. Due to the state of the mother,
nursing did not occur. The child was tracked during its first year and presented with anemia
and splenomegaly. A biopsy of the spleen revealed the presence of Leishman-Donovan bodies
[65], indicating that vertical transmission of leishmaniasis had occurred.
The epidemiological antecedents of leishmaniasis are crucial when pediatric patients or those
of childbearing age develop symptoms suggestive of leishmaniasis. A mother who was
diagnosed with L. infantum by ELISA had been on a farm when she was between 28 and 30
weeks pregnant. The child was born by elective caesarean at 38 weeks in a non-endemic zone
in the Ukraine. At the age of eight months, the nursing child suddenly exhibited a fever,
decreased appetite, weakness, pallor of the integuments, bruising, hepatosplenomegaly,
tachypnea, and lymphadenopathy. An aspirate of the bone marrow revealed ovoid cells of 3-5
µm that were identified as Leishman-Donovan bodies [66].
In Germany, there have been two reported cases of leishmaniasis involving mothers who
visited endemic zones prior to their pregnancies. The first case involved a 16-month-old
pediatric patient with visceral leishmaniasis whose mother had traveled to endemic zones two
years earlier [67]. The second case was a 15-month-old child with visceral leishmaniasis whose
mother was on a farm in an endemic zone between 20 and 22 weeks of pregnancy [68].
Chronic visceral leishmaniasis has been linked to premature birth and materno-fetal deaths.
[69] A histological analysis of the placenta and an aspirate of the lymphatic ganglion revealed
the presence of thrombotic, vascular changes in the placenta of a fetus at five months of
gestation in a mother that had been infected with leishmaniasis for two months [70]. Neonates
carried to term from infected mothers have remained asymptomatic during the first weeks or
months of life. However, Leishman bodies have ultimately been detected in the bone marrow,
and anti-Leishmania antibodies have also been detected, corroborating the diagnosis of
leishmaniasis [65, 69, 71].
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Leishmaniasis can be accompanied by concomitant infections by organisms from similar
genera. During the second trimester, a pregnant patient was initially treated for leishmaniasis
and showed improvement at 30 days. The baby was born vaginally at 36 weeks without
complications and weighed 1,700 grams. He was readmitted three days later for deterioration
due to probable malaria and tuberculosis, but he did not show improvement following
treatment. Amastigotes were detected in an aspirate of the lymphatic ganglion of the mother.
In addition, IgG antibodies were detected in the baby; these antibodies were attributed to
passive transplacental transfer of parasite-specific antibodies from the mother to the fetus,
negating the need for treatment. He was admitted once more at seven months old for symp‐
toms suggestive of Plasmodium falciparum, and he did not show improvement upon treatment.
A bone marrow aspirate revealed Leishmania. However, despite treatment, the infant died. An
autopsy revealed that the presence of abundant Leishmania parasites in the kidneys, spleen,
thymus, bone marrow, liver, and lungs and Candida spp. in the respiratory tract [70].
Individuals, whether mother or offspring, in endemic zones can be infected for months or years
prior to the onset of symptoms. For example, a woman visited an endemic zone and became
pregnant two years later. She did not experience any symptoms during her pregnancy or post-
partum while in the non-endemic zone nor was there evidence of the existence of the vector
in the geographic area. While the mother remained asymptomatic, the infant exhibited
symptoms of possible visceral leishmaniasis, which was confirmed by various laboratory tests
[67].
There is evidence that cutaneous leishmaniasis is associated with perinatal health problems,
as has been observed in Brazil, where women with L. braziliensis-mediated cutaneous leish‐
maniasis developed vegetative or atypical lesions at the 18th week of pregnancy. Of these
patients, 10% delivered prematurely and the fetus died in another 10% of the cases. A biopsy
of one of the fetuses revealed intense inflammatory exudates predominated by neutrophils,
and parasites were detected by electrophoresis [72].
2.4.2. Congenital leishmaniasis in animals
In Brazil, a trial was performed with asymptomatic and symptomatic mixed-breed dogs that
were infected with L. donovani and L. infantum. There were four dogs in each group, and the
livers, spleens, lymph nodes, bone marrow, kidneys, and hearts of their offspring were
analyzed by PCR for infection. The numbers of offspring obtained from symptomatic or
asymptomatic mothers (26 vs. 27) were nearly identical. The placentas and the offspring were
analyzed by PCR, and 13 of the 26 placentas and 9 of the 26 offspring of the symptomatic
mothers were positive for the parasite, while 13 of the 27 placentas and 8 of the 27 offspring
from the asymptomatic mothers were positive. Furthermore, it was noted that PCR was more
sensitive for parasite detection in comparison to immunohistochemistry and hematoxylin and
eosin staining [73]. Another study in Italy involved seven female dogs that had been diagnosed
with leishmaniasis by serology, microscopy, and PCR. Two of the seven were treated with N-
methylglucamine prior to pregnancy, and one of the seven was treated during pregnancy. The
pups were examined between 3 and 30 days of age. The parasite was detected in 8 of the 31
pups in both groups, and only 2 of the 8 pups developed symptoms [74].
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2.4.3. Experimental models of congenital transmission
In a murine model of visceral leishmaniasis, twenty 12-week -old female BALB/c mice were
infected with L. infantum. They were mated 8 weeks later with healthy males, and the females
were sacrificed at days 13 and 18 of gestation. The offspring were sectioned in half for PCR
analysis. In 15 of the 20 pregnant mice, the parasite was detected by PCR in the spleen. In the
offspring, 3 of the 88 placentas and 4 of the 88 pups tested positive for Leishmania by PCR [75].
In studies to determine vertical transmission of Leishmania in beagles, parasitemia was detected
in the liver, spleen, and bone marrow of the offspring [63].
In experimental model in which hamsters were infected with 106 parasites/mL of L. panamen‐
sis during the first week of pregnancy, 24 of 93 (25.8%) of the offspring from infected mothers
were PCR positive to Leishmania, 2 months after the birth [76]. Furthermore, mice infected with
high inoculums of L. mexicana strain, known as cause of cutaneous leishmaniasis, showed that
all female and their placentas were positive to PCR analysis, and revealed that the infection
was present in 39 of 110 offspring of infected mothers, also fetal deaths and resorptions were
observed [77]. Then is important to be aware to the fact that leishmaniasis could be transmitted
transplacentally and causes fetal resorption, death, and reduction in offspring body weight.
2.5. Other factors related to substance abuse and work environment
2.5.1. Drug use
In cases of leishmaniasis infection due to fomites, such as sharp, contaminated objects, the most
vulnerable population are illicit drug users. In a Spanish study of syringes used for recreational
drug use, it was reported that 32-52% of the syringes were contaminated by Leishmania, as
determined by PCR. Moreover, 3 different genotypes were identified in multiple samples,
confirming that the individuals had shared syringes. Therefore, programs that limit the sharing
of needles should decrease the infection rate among vulnerable individuals [78-79].
2.5.2. Work environment transmission
As described above, Leishmania spp. can be transmitted through fluids such as blood and by
contact with animals or even contaminated objects. In all cases, there must be an entry route,
which is usually a wound. In staffs dedicated to clinical, diagnostic or medical research, it is
not uncommon to find reported cases of Leishmania infection, although many such likely go
unrecognized [80]. Infections due to accidental exposure can be affected by a variety of factors,
including kinematics (e.g., the path and characteristics of exposure and the amount of
inoculum), parasite characteristics (e.g., pathogenicity, virulence, viability and infective dose)
and host characteristics (e.g., immune status, barrier status and actions following the accident)
[80]. However, the possibility of infection due to vector exposure in an endemic region should
not be ruled out when performing questioning [81]. The first case of work-related leishmaniasis
was reported in 1930, and to date, there have been 12 reported cases of Leishmania infection
due to accidents at work; these have included 6 different Leishmania species, with L. donovani
being implicated in half of the affected individuals. In these cases, the incubation period ranged
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from 3 weeks to 8 months after the accident. Although the United States is not considered to
be an endemic region, it has had more than half of reported leishmaniasis cases of laboratory
transmission, with the parenteral route being the most frequent means of exposure, followed
by animal bites, primarily from experimental animals. In one affected population, the average
age of leishmaniasis cases due to work-related accidents was 30, and four of the affected
individuals were students [80].
According to the CDC, the Leishmania parasite is considered to be a Biosafety Level 2 (BSL-2)
organism, which implies that the individual transmission rate is moderate, and low in the case
of a community. Therefore, Leishmania can cause disease in humans or animals without being
considered a serious risk for laboratory staff. Although exposure can lead to serious infection,
effective treatments are available and the risk is limited [82]. Potentially infectious parasites
can be found in blood, tissues, exudates and infected arthropods, and they can be transmitted
through wounds, micro-abrasions, accidental parenteral inoculation or transmission by
arthropods [80]. Therefore, it is recommended that all staff having contact with potentially
infectious material use protective equipment and that the handling of potentially infectious
waste be carried out in accordance with appropriate regulations and good clinical/laboratory
practices [80, 82]. In the case of staff with compromised immune systems, it is recommended
that they avoid work with live organisms [82].
3. Conclusions
The Leishmania parasite can survive in a wide range of temperatures and pH conditions, which
has allowed it to adapt to the diverse conditions encountered within different vector and host
species. In recent years, transmission pathways other than those based on vector species have
been described, including invasive procedures for therapeutic purposes, sexual practices,
pregnancy, drug practices and work-related accidents among health/research staff members,
all of which have led to an increase in the number of reported leishmaniasis cases. However,
considering that the latency period of the parasite within the host can last up to one year, there
are likely more infected individuals than those that have been reported. Because leishmaniasis
is not considered to be a disease that can be transmitted between individuals without the
intervention of a vector species, laboratory tests for the presence of these parasites to rule out
prospective donors are not carried out prior to in most invasive therapeutic procedures.
However, in the case of patients with immunodeficiency, the possibility of contracting the
disease is significantly increased. Furthermore, during pregnancy, changes to the immune
system can allow for the transmission of the parasite from the mother to the fetus. It should
also be noted that maternal-fetal infection can also be of sexual origin. Among drug addicts,
it was demonstrated that syringe sharing is a significant source of infection. Finally, in addition
to populations exposed in endemic areas, staff working in the health or research sectors should
also be considered as populations at risk of acquiring this disease.
Taken together, there is a clear need for the health system to reevaluate the global situation
concerning leishmaniasis transmission and to implement strategies to reduce the exposure of
individuals to Leishmania infections.
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